FY2025 EPS Estimates for Genfit Decreased by Leerink Partnrs

Genfit S.A. (NASDAQ:GNFT) – Research analysts at Leerink Partnrs reduced their FY2025 EPS estimates for shares of Genfit in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now anticipates that the company will post earnings per share of ($0.88) for the year, down from their prior estimate of ($0.86). The consensus estimate for Genfit’s current full-year earnings is $0.96 per share. Leerink Partnrs also issued estimates for Genfit’s FY2026 earnings at ($0.84) EPS, FY2027 earnings at ($0.35) EPS and FY2028 earnings at ($0.88) EPS.

Separately, HC Wainwright restated a “buy” rating and issued a $13.00 price target on shares of Genfit in a research note on Friday.

Genfit Stock Performance

Shares of GNFT opened at $3.91 on Friday. Genfit has a twelve month low of $3.35 and a twelve month high of $6.42. The firm has a 50 day moving average of $3.76 and a 200 day moving average of $4.43. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.74 and a quick ratio of 3.74.

About Genfit

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.